ProNAi Therapeutics, Inc. Announces New Scientific Advisory Board
KALAMAZOO, Mich.--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that it has named its new Scientific Advisory Board team, composed of distinguished researchers and professionals in genomics, oligonucleotides, preclinical and clinical drug development.